x
Filter:
Filters Applied
- Editorials
- EditorialRemove Editorial filter
Publication Date
Please choose a date range between 2004 and 2021.
Author
- Yee, Jerry62
- Brown, Wendy Weinstock10
- Weinstock Brown, Wendy9
- Thakar, Charuhas V6
- Nast, Cynthia C3
- Novak, James E3
- Batlle, Daniel2
- Bleyer, Anthony J2
- Campbell, Ruth C2
- Davis, Connie L2
- Fadem, Stephen Z2
- Heung, Michael2
- Liu, Kathleen D2
- McCullough, Peter A2
- McGill, Janet B2
- Molony, Donald A2
- Soman, Sandeep2
- Adams, Beth1
- Agarwal, Anil K1
- Ahmed, Nahreen1
- Arruda, Jose1
- Arthur, John M1
- Asif, Arif1
- Avasare, Rupali S1
- Barisoni, Laura1
Editorials
170 Results
- Editorial
Treatment of Diabetic Nephropathy: Changing Landscapes and New Horizons
Advances in Chronic Kidney DiseaseVol. 28Issue 4p279Published in issue: July, 2021- Charuhas V. Thakar
Cited in Scopus: 1Until the early 19th century, diabetes mellitus (DM) was regarded as a disease of the kidney, in which one of the signs was that of an increase in the volume of urine and wasting. Only after the identification of glucose in blood and urine in the late 18th century was it recognized as a metabolic disorder. It was noted in parallel that patients with DM may show presence of coagulable urine containing albumin as a sign of kidney disease. After the advent of availability of insulin in the early 1920s, which led to increased survival, diabetic nephropathy became more apparent. - Guest Editorial
A New Therapeutic Era in the Management of Diabetic Kidney Disease
Advances in Chronic Kidney DiseaseVol. 28Issue 4p280–281Published in issue: July, 2021- Sylvia E. Rosas
- David Z.I. Cherney
Cited in Scopus: 1Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) worldwide. After 2 decades of negative trials, in the last few years there has been a major and welcome shift in the therapeutic options to treat DKD. Nephrologists will be in the forefront of implementation of these new therapies as well as in the education of their colleagues and patients on the benefits and possible side effects of these novel therapies. - Guest Editorial
The Ultrasound-Augmented Physical Exam for Nephrologists: Beyond the Kidney
Advances in Chronic Kidney DiseaseVol. 28Issue 3p191–192Published in issue: May, 2021- Nathaniel Reisinger
- Nahreen Ahmed
Cited in Scopus: 0Recent developments in handheld ultrasound technology, including cloud-based image archiving, artificial intelligence–enhanced image guidance, and the development of the capacitive micromachined ultrasound transducer—a microchip alternative to conventional piezoelectrics—are driving down the cost of ultrasound devices and facilitating image acquisition for novice learners. These technologic adaptations lower the barrier for entry and accelerate an already burgeoning trend of adoption of point-of-care ultrasound (POCUS) among medical providers. - Guest Editorial
Home Hemodialysis
Advances in Chronic Kidney DiseaseVol. 28Issue 2p123Published in issue: March, 2021- Madhukar Misra
Cited in Scopus: 0This special issue of ACKD on home hemodialysis (HHD) represents a timely reflection on the state of HHD in the United States. President Trump's executive order of July 2019 (Advancing American Kidney Health Initiative) laid out an ambitious agenda for expanding the use of home dialysis and preemptive kidney transplantation in the United States. This issue is a compendium of articles that are wide in their breadth and scope, representing an attempt to address a variety of issues involved in implementing such a complex and difficult task. - Editorial
Dialysis: Please Try This at Home!
Advances in Chronic Kidney DiseaseVol. 28Issue 2p121–122Published in issue: March, 2021- Charuhas V. Thakar
Cited in Scopus: 0Yes, in 2021, we are able to say that the quality of life and freedom to do the things we love can be possible while on dialysis. A special mention to the photograph on the cover of this issue dedicated to home hemodialysis (see credits in the issue), which exemplifies that. - Guest Editorial
Nephrology Critical Care: A Darwinian Evolution
Advances in Chronic Kidney DiseaseVol. 28Issue 1p1–2Published in issue: January, 2021- Javier A. Neyra
- Michael Heung
Cited in Scopus: 0While hospitals across the nation continue to expand their capacity to care for critically ill patients, the practice of medicine in the intensive care unit (ICU) has evolved from being solo intensivist-driven to a multidisciplinary care model. The latter involves a myriad of clinicians as well as pharmacists, physical therapists, nutritionists, and subspecialists that usher a diverse and complementary expertise.1 Among many subspecialists in the ICU, the nephrologist serves as an invaluable asset in many commonly encountered conditions, including electrolyte/acid-base derangements and most notably acute kidney injury (AKI). - Guest Editorial
COVID-19 and the Kidney Community: Coalescing in Crisis
Advances in Chronic Kidney DiseaseVol. 27Issue 5p362–364Published online: October 26, 2020- Silvi Shah
- Matthew A. Sparks
Cited in Scopus: 1The coronavirus disease 2019 (COVID-19) pandemic has led to significant changes to the practice of kidney medicine. The ability to provide acute dialysis is strained due to high rates of acute kidney injury (AKI), which occurs in up to 30% to 40% of hospitalized patients. The presence of AKI in the setting of COVID-19 is associated with high morbidity and mortality.1 Figure 1 illustrates various manifestations of COVID-19 in the kidney. The need for social distancing has resulted in a shift to outpatient telemedicine for many patients with kidney disease. - Guest Editorial
Reenvisioning the Adult Nephrology Workforce: The Future of Kidney Care in the United States
Advances in Chronic Kidney DiseaseVol. 27Issue 4p279–280Published in issue: July, 2020- Samira S. Farouk
- Matthew A. Sparks
Cited in Scopus: 1The cover image in this issue of Advances in Chronic Kidney Disease illustrates the various components (pieces) that make up the nephrology workforce. Although our nephrology community strives to complete this puzzle, these pieces are dynamic and constantly evolving. It is up to our community to react to changes in kidney care to ensure our workforce is able to provide optimal care for patients with kidney disease. - Editorial
Future of Nephrology Workforce: Reimagining Educational Value
Advances in Chronic Kidney DiseaseVol. 27Issue 4p277–278Published in issue: July, 2020- Charuhas V. Thakar
Cited in Scopus: 0The definition of this term states “people engaged in or available for work in any enterprise or company”. Should we be satisfied in simply creating the future workforce? Or should we redefine in how we even articulate what the future of our profession may look like? Should we not be raising the bar to say that we want to nurture the next generation of compassionate and astute clinicians, scientists, and leaders? If so, then we need to reimagine how to do that and tread with caution as we pass on the knowledge to that generation. - Guest Editorial
Dialysis Access: The Future Is Already Here
Advances in Chronic Kidney DiseaseVol. 27Issue 3p168–170Published in issue: May, 2020- Anil K. Agarwal
- Bharvi P. Oza-Gajera
Cited in Scopus: 1At the time of this writing, we are in the midst of a full-blown pandemic – the likes of which none of us have seen in our lifetimes. It is in times such as these that our profession and the care of our patients is seen through an unfiltered lens. The American Society of Diagnostic and Interventional Nephrology and the Vascular Access Society of the Americas in an effort to protect the mainstay of our patients' access to adequate dialytic care came together to publish a joint statement in March of 2020 sharing that maintaining dialysis accesses “will be instrumental in maintaining health and survival for patients with end-stage kidney disease (ESKD) as well as protecting hospitals from an eventual wave of high urgency/emergency procedures to deal with lost dialysis accesses.” Dialysis access truly is the lifeline of our patients – the infamous “Achilles Heel,” and in these dire times, our patients' need for a reliable, low-risk access becomes blatantly obvious. - Editorial
Interventional Nephrology: What, Who, Why?
Advances in Chronic Kidney DiseaseVol. 27Issue 3p167Published in issue: May, 2020- Charuhas V. Thakar
Cited in Scopus: 0These 2 words can mean different things from a patient's or a provider's perspective. For the patient, it is a “lifeline” to undergo a life-sustaining treatment, day after day, and lack of an optimal access can literally be a death sentence. Whether be it lack of achieving or maintaining the vascular access. - Guest Editorial
O Complement, Where Aren't Thou
Advances in Chronic Kidney DiseaseVol. 27Issue 2p83–85Published in issue: March, 2020- C. John Sperati
- Shruti Chaturvedi
Cited in Scopus: 0The innate immune system represents the oldest arm of mammalian host defense, of which the complement cascade is of paramount importance. Complement serves several roles, including direct cellular killing, tagging of foreign and self-debris for cell-mediated clearance, and modulation of the adaptive immune response. The Human Genome Organization Gene Nomenclature Committee recognizes 56 proteins within the complement pathway. Given this complexity, most medical students and clinicians devote little time to understanding the intricacies of the cascade. - Guest Editorial
Poisoning, Toxicology, and the Nephrologist
Advances in Chronic Kidney DiseaseVol. 27Issue 1p3–4Published in issue: January, 2020- Nikolas Harbord
Cited in Scopus: 1In 2017, the American Association of Poison Control Centers reported more than 2.1 million human toxic exposures across the United States. In fact, toxic exposures with serious outcomes have increased every year since 2000.1 Although the 3208 resulting or related deaths were far fewer than the total referrals and interventions, concerns remain. Most reported exposures were due to a few classes of prescription medications (analgesics, sedative/hypnotics, antipsychotics, antidepressants) or readily available cleaning or personal care products. - Editorial
Toxicology and Kidney: Not so Innocent Bystander
Advances in Chronic Kidney DiseaseVol. 27Issue 1p1–2Published in issue: January, 2020- Charuhas V. Thakar
Cited in Scopus: 0Patients are exposed to numerous prescribed and over-the-counter medications. Unfortunately, drugs remain a relatively common cause of acute and chronic kidney injury. By some estimates, up to 1-in-3 cases of acute kidney injury (AKI) can be attributed to the effect of prescribed drugs and endogenous/exogenous toxins. However, establishing causality in drug-induced kidney disease is challenging and requires knowledge of the biological plausibility of the agent, mechanism of injury, time course, and assessment of competing risk factors. - Editorial
Advances in Chronic Kidney Disease as Syntopicon
Advances in Chronic Kidney DiseaseVol. 26Issue 6p405–406Published in issue: November, 2019- Jerry Yee
Cited in Scopus: 0Advances in Chronic Kidney Disease began its life under the aegis of Allen R. Nissenson as the first Editor-in-Chief of Advances in Renal Replacement Therapy.1 Dr. Nissenson's expressed desire was for A-R-R-T to become the “art” of renal replacement therapy. He explicitly stated this aspiration, echoing the enthusiastic prose of Dr. Seuss, in his inaugural editorial in April 1994, “The ARRT of Uremia Therapy.”1 Instrumental to the journal's conception was much the effort of Garabed Eknoyan—a long-time advisor-contributor to the National Kidney Foundation in so many ways. - Guest Editorial
Cardiovascular Calcifications Among Patients With Uremia: Answers to Hard Questions
Advances in Chronic Kidney DiseaseVol. 26Issue 6p407–408Published in issue: November, 2019- Sagar U. Nigwekar
Cited in Scopus: 1A 56-year-old woman with long-standing history of diabetes mellitus and end-stage renal disease is evaluated for severely painful indurations covering both thighs. She is obese and has been on warfarin therapy for atrial fibrillation. A skin biopsy obtained from the indurated area demonstrates calcifications involving subcutaneous arterioles and adjacent adipocytes. A diagnosis of uremic calciphylaxis is made. Prior radiological examinations demonstrate diffuse arterial and valvular calcifications involving coronary, mesenteric, carotid, femoral and aortic beds, and mitral and tricuspid valves. - Editorial
Lupus Nephritis: Breaking the Lull
Advances in Chronic Kidney DiseaseVol. 26Issue 5p307–310Published in issue: September, 2019- Rupali S. Avasare
- Jerry Yee
Cited in Scopus: 1Systemic lupus erythematosus (SLE) has a prevalence of 241 per 100,000 people in the United States.1 Young women are disproportionately affected and disease burden is highest in blacks and lowest in whites in studies that report data by race.1 Up to 75% of SLE patients will develop kidney disease, which is often asymptomatic and detected only by urinalysis. Pathologic classification of lupus nephritis (LN) is based on the location and degree of glomerular involvement coupled with the activity and chronicity of histologic changes. - Guest Editorial
Lupus Nephritis: How Far Have We Come, and Where Are We Headed?
Advances in Chronic Kidney DiseaseVol. 26Issue 5p311–312Published in issue: September, 2019- Iris J. Lee
- Samir V. Parikh
Cited in Scopus: 1Of all the organ domains involved in systemic lupus erythematosus (SLE), renal disease is associated with the greatest morbidity and mortality. Relative age-adjusted mortality in SLE patients with renal disease compared to those without is greater at every level of renal involvement and stage of CKD.1,2 Recent data show decreased trends in the burden of end-stage renal disease (ESRD) due to lupus nephritis (LN) in the United States. However, greater than 50% of SLE patients will develop LN and an unacceptably high number (up to 44% of patients with class III or IV LN) progress to ESRD by 15 years requiring renal replacement therapy in the form of dialysis or kidney transplant. - Editorial
Erythropoiesis-Stimulating Agents and Cancer: Myth or Truth
Advances in Chronic Kidney DiseaseVol. 26Issue 4p221–224Published in issue: July, 2019- Michael J. Choi
- Jerry Yee
Cited in Scopus: 0Erythropoiesis-stimulating agents (ESAs) have been implicated in causing cancer progression. This belief has been largely based on trials in the early 2000s of ESA use in malignancy with high hemoglobin (Hgb) targets and large ESA doses to attain the targets. More recent trials using ESA doses with Hgb targets similar to current goal levels in CKD have not confirmed this increased risk of cancer progression for most malignancies. - Guest Editorial
Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?
Advances in Chronic Kidney DiseaseVol. 26Issue 4p225–228Published in issue: July, 2019- Jay B. Wish
Cited in Scopus: 1The publication date of this issue of ACKD, July-August 2019, is almost exactly 30 years after the approval by the Food and Drug Administration (FDA) of epoetin alfa in June 1989. There has been considerable evolution in the treatment of anemia in patients with CKD since that time despite the fact that erythropoietic stimulating agents (ESAs) remain the mainstay of that therapy. In the 1990s, we discovered the necessity of adequate iron supplementation to achieve the targeted erythropoietic response to ESAs. - Editorial
Eradicating the Viral Triad in Hemodialysis Units
Advances in Chronic Kidney DiseaseVol. 26Issue 3p157–161Published in issue: May, 2019- Beth Adams
- Jerry Yee
Cited in Scopus: 2In this issue of Advances in Chronic Kidney Diseases, Dr James Novak as Guest Editor has curated a collection of manuscripts from a cadre of nephrologists whose curiosity includes the viral nephropathies. The authors present a well-researched group of articles that comprehensively review the vast majority of contemporary viral disorders with which most nephrologists will engage at some point in their careers. However, the bulk of nephrologists will be concerned with 3 viruses more than others, hepatitis C virus (HCV), hepatitis B virus (HBV), and the human immunodeficiency virus-1 (HIV). - Guest Editorial
Warning: Kidney Virus Detected
Advances in Chronic Kidney DiseaseVol. 26Issue 3p162–163Published in issue: May, 2019- James E. Novak
Cited in Scopus: 0The variety of genes on the planet in viruses exceeds, or is likely to exceed, that in all of the rest of life combined. —Edward O. Wilson In 1993, the number of viruses that infected vertebrates, specifically mammals, was estimated at 1,000,000 and 320,000, respectively.1 By 2012, 219 human virus species had been identified, with 3–4 novel viruses projected to emerge each year from mammalian and avian reservoirs.2 Advances in genetics during the past few decades have facilitated the detection of more and more occult viruses, previously unrecognized within the human genome, the accumulation of which is collectively known as the human virome. - Editorial
Dr. Conn Lives on: Insights Into Screening and Genetics of Primary Aldosteronism
Advances in Chronic Kidney DiseaseVol. 26Issue 2p81–84Published in issue: March, 2019- Debbie L. Stein
- Jerry Yee
Cited in Scopus: 2This issue of Advances in Chronic Kidney Disease features an old standard, hypertension. This topic is reviewed periodically. This time, Dr. Kausik Umanath has taken up the gauntlet to press forward our collective mission to diagnose and treat this most fundamental medical problem early, accurately, and efficiently. In this issue, the variegation of the pathophysiology of hypertension will be revealed along with its treatments. In Dr. Umanath's Guest Editorial, you will see a glimpse of what is contained within, but first, a story. - Guest Editorial
Hypertension: A Common but Complex Condition
Advances in Chronic Kidney DiseaseVol. 26Issue 2p85–86Published in issue: March, 2019- Kausik Umanath
Cited in Scopus: 0Hypertension is a common condition known to cause significant cardiovascular events including death, stroke, and heart failure.1,2 Our understanding of the pathogenesis and optimal approaches to therapy has evolved tremendously over the past 50 years.3 Despite these advances, only 50% of individuals achieve blood pressure control according to National Health and Nutrition Examination Surveys 2015-2016 data.4 Hypertension remains a significant global health problem, and in this issue of Advances in Chronic Kidney Disease, we have put together a set of manuscripts covering several key issues in both the pathogenesis and management of hypertension. - Guest Editorial
The Many Faces of Infection in CKD: Evolving Paradigms, Insights, and Novel Therapies
Advances in Chronic Kidney DiseaseVol. 26Issue 1p5–7Published in issue: January, 2019- Mohanram Narayanan
Cited in Scopus: 4In 1961, Schreiner was the first to note unique susceptibility to infection among patients with kidney failure.1 It was assumed that general debility from chronic uremia increased the risk of infection; thus, it was postulated that reversal of the uremic state would reduce the risk of infection.2 Unfortunately, kidney replacement therapy has not reduced the problem of infection; it has only changed the paradigm.3 Dialysis superimposes myriad new problems onto patients already suffering relentless deterioration from underlying multisystem disease and poor wound healing.